Stockscreener 앱 받기
14.44
6.57%
0.89
시간 외 거래:
14.60
0.16
+1.11%
전일 마감가:
$13.55
열려 있는:
$13.64
하루 거래량:
1.53M
Relative Volume:
1.60
시가총액:
$887.45M
수익:
-
순이익/손실:
$-221.04M
주가수익비율:
-3.8877
EPS:
-3.7143
순현금흐름:
$-178.65M
1주 성능:
+19.83%
1개월 성능:
-8.20%
6개월 성능:
+50.57%
1년 성능:
+73.56%
1일 변동 폭
$13.63
$15.25
1주일 범위
$11.97
$15.25
52주 변동 폭
$5.68
$16.74
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
14.44 | 836.44M | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 개시 | Citigroup | Buy |
| 2026-02-02 | 개시 | Guggenheim | Buy |
| 2025-08-21 | 재개 | H.C. Wainwright | Buy |
| 2025-06-11 | 재개 | Stifel | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-05-01 | 개시 | Stifel | Buy |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-06-15 | 개시 | TD Cowen | Outperform |
| 2022-11-21 | 개시 | BTIG Research | Buy |
| 2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 개시 | Evercore ISI | Outperform |
| 2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 개시 | SVB Leerink | Outperform |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
CGEM Stock Price, Quote & Chart - ChartMill
CGEM Reiterated by Wedbush -- Price Target Maintained at $37 - GuruFocus
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics reports remissions in SLE, RA with CLN-978 - scanx.trade
William Blair reiterates Cullinan Oncology stock rating on trial data By Investing.com - Investing.com South Africa
William Blair reiterates Cullinan Oncology stock rating on trial data - Investing.com
CGEM: CLN-978 and velinotamig show breakthrough efficacy and safety in refractory autoimmune diseases - TradingView
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune DiseasesSlideshow (NASDAQ:CGEM) 2026-06-10 - Seeking Alpha
Cullinan Therapeutics (CGEM) Reports Positive Clinical Developme - GuruFocus
CGEM: T cell engagers show robust efficacy in RA and SLE, with expanded trials planned for 2027 - TradingView
Cullinan reports clinical data for autoimmune drug candidates - Investing.com UK
CGEM: CLN-978 and velinotamig advance toward Phase 2 after strong efficacy and safety in SLE and RA - TradingView
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data - TipRanks
Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps - Moomoo
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases - The Manila Times
Cullinan Therapeutics Shares New Clinical Data Across Its - GlobeNewswire
Cullinan Therapeutics shares positive Phase 1 data for CLN-978 and velinotamig, outlines next‑stage plans - TradingView
Cullinan Therapeutics (NASDAQ: CGEM) shares new autoimmune trial results - Stock Titan
Cullinan Aims for Autoimmune 'Reset' with T Cell Engager Data - BriefGlance
Cullinan Therapeutics details new biomarker approach for immune reset in autoimmune disease research - Traders Union
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO) - The Globe and Mail
Cullinan TherapeuticsExpanding The Reach Of T Cell Engagers Beyond Cancer - RTTNews
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $38 - Moomoo
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $30 - GuruFocus
Cullinan Therapeutics Reports Promising Phase 1 Data for CLN-978 CD19xCD3 T Cell Engager in SLE and RA at EULAR 2026 Congress - Minichart
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data - TipRanks
Cullinan Therapeutics shares Phase 1 CLN-978 data showing deep B-cell depletion and clinical responses - TradingView
Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data - Stock Titan
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at E - GuruFocus
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at EULAR Congress - GuruFocus
Cullinan Therapeutics Inc Cln-978 Shows Favorable Safety Profile With Single Target Doses Up To 30 Μg As Well As Initial Multi-Dose Regimen - TradingView
Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA - Traders Union
Cullinan Therapeutics Reports Positive Clinical Data for CLN-978 in Treating Systemic Lupus Erythematosus and Rheumatoid Arthritis - Quiver Quantitative
Cullinan Therapeutics Presents Initial Clinical Data for - GlobeNewswire
Cullinan Therapeutics Presents Initial Clinical Data for Cln-978, A Cd19xcd3 T Cell Engager, At the Eular 2026 Congress - marketscreener.com
Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors - TipRanks
Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments - Traders Union
Number of shareholders of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $38 - Moomoo
CGEM Technical Analysis | Trend, Signals & Chart Patterns | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill
Cullinan Therapeutics (CGEM) Stock Analysis Report | Financials & Insights - Benzinga España
Cullinan Therapeutics (CGEM) Retreats 1% as Stock Approaches Support ZoneIV Percentile - The Legal Advocate
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), Cullinan Management (CGEM) - The Globe and Mail
Cullinan Therapeutics (CGEM) Plans Immunology Day Event in NYC - GuruFocus
CGEM - Finviz
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager - The Manila Times
Cullinan Therapeutics to Host Immunology Day to Showcase - GlobeNewswire
Wedbush maintains Cullinan Therapeutics (CGEM) outperform recommendation - MSN
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics, Inc. $CGEM Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
쿨리난 온콜로지 주식 (CGEM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
May 05 '26 |
Sale |
14.62 |
8,000 |
116,996 |
166,844 |
2.60%
0.94%
자본화:
|
볼륨(24시간):